| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CXI Healthcare Technology Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩101.00 |
| 52 Week High | ₩166.00 |
| 52 Week Low | ₩96.00 |
| Beta | 1.14 |
| 11 Month Change | -7.34% |
| 3 Month Change | -11.40% |
| 1 Year Change | -34.42% |
| 33 Year Change | -67.94% |
| 5 Year Change | -73.70% |
| Change since IPO | -96.96% |
Recent News & Updates
Shareholder Returns
| A900120 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | 0% | -9.5% | -0.05% |
| 1Y | -34.4% | 21.1% | 6.0% |
Return vs Industry: A900120 underperformed the KR Personal Products industry which returned 23.1% over the past year.
Return vs Market: A900120 underperformed the KR Market which returned 5% over the past year.
Price Volatility
| A900120 volatility | |
|---|---|
| A900120 Average Weekly Movement | 5.4% |
| Personal Products Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A900120 has not had significant price volatility in the past 3 months.
Volatility Over Time: A900120's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 10 | Jin Lin | www.ckhfnh.co.kr |
CXI Healthcare Technology Group Limited engages in the manufacture and distribution of health foods. It primarily offers Chinese medicine-based health supplements in capsule, tablet, drink, and tea forms. The company was formerly known as CKH Food & Health Limited and changed its name to CXI Healthcare Technology Group Limited in October 2023.
CXI Healthcare Technology Group Limited Fundamentals Summary
| A900120 fundamental statistics | |
|---|---|
| Market cap | ₩29.11b |
| Earnings (TTM) | ₩21.01b |
| Revenue (TTM) | ₩67.19b |
1.4x
P/E Ratio0.4x
P/S RatioIs A900120 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A900120 income statement (TTM) | |
|---|---|
| Revenue | ₩67.19b |
| Cost of Revenue | ₩41.10b |
| Gross Profit | ₩26.09b |
| Other Expenses | ₩5.08b |
| Earnings | ₩21.01b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 72.90 |
| Gross Margin | 38.83% |
| Net Profit Margin | 31.27% |
| Debt/Equity Ratio | 0% |
How did A900120 perform over the long term?
See historical performance and comparison